Next Article in Journal
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Bordetella bronchiseptica Co-Infection in a Stem Cell Transplant Patient
Next Article in Special Issue
Guanidinylated Polymyxins as Outer Membrane Permeabilizers Capable of Potentiating Rifampicin, Erythromycin, Ceftazidime and Aztreonam against Gram-Negative Bacteria
Previous Article in Journal
Prediction of Potential Natural Antibiotics Plants Based on Jamu Formula Using Random Forest Classifier
Previous Article in Special Issue
Evaluating the Effectiveness of Hospital Antiseptics on Multidrug-Resistant Acinetobacter baumannii: Understanding the Relationship between Microbicide and Antibiotic Resistance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 11
Issue 9
10.3390/antibiotics11091201
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

by
Janna Michaeli
1,
Shira Mandel
1,
Shelly Maximov
1,
Jonathan Zazoun
1,
Paola Savoia
2,
Nimmi Kothari
3,
Thomas Valmont
3,
Livia Ferrari
2,
Leonard R. Duncan
4,
Stephen Hawser
3,
Moshe Cohen-Kutner
1 and
Niv Bachnoff
1,*
1
Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9270401, Israel
2
Evotec Anti-Infective, Department of Microbiology Discovery, Aptuit (Verona) Srl, an Evotec Company, Via A. Fleming 4, 37135 Verona, Italy
3
IHMA Europe Sàrl, Route de l’Ile-au-Bois 1A, 1870 Monthey, Switzerland
4
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
*
Author to whom correspondence should be addressed.
Antibiotics 2022, 11(9), 1201; https://doi.org/10.3390/antibiotics11091201
Submission received: 17 August 2022 / Revised: 31 August 2022 / Accepted: 1 September 2022 / Published: 5 September 2022
(This article belongs to the Special Issue Novel Antimicrobial Strategies to Combat Multidrug-Resistant (MDR) Gram-Negative Bacteria)
Browse Figures
Versions Notes

Abstract

The rapid worldwide spread of antimicrobial resistance highlights the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. This study describes the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii clinical isolates. OMN6 prevented the growth of all tested isolates, regardless of any pre-existing resistance mechanisms. Moreover, in vitro serial-passaging studies demonstrated that no resistance developed against OMN6. Importantly, OMN6 was highly efficacious in treating animal models of lung and blood infections caused by multidrug-resistant A. baumannii. Taken together, these results point to OMN6 as a novel antimicrobial agent with the potential to treat life-threatening infections caused by multidrug-resistant A. baumannii avoiding resistance.
Keywords: OMN6; antimicrobial peptides; antimicrobial resistance; AMR; Acinetobacter baumannii; infectious diseases OMN6; antimicrobial peptides; antimicrobial resistance; AMR; Acinetobacter baumannii; infectious diseases

Share and Cite

MDPI and ACS Style

Michaeli, J.; Mandel, S.; Maximov, S.; Zazoun, J.; Savoia, P.; Kothari, N.; Valmont, T.; Ferrari, L.; Duncan, L.R.; Hawser, S.; et al. In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii. Antibiotics 2022, 11, 1201. https://doi.org/10.3390/antibiotics11091201

AMA Style

Michaeli J, Mandel S, Maximov S, Zazoun J, Savoia P, Kothari N, Valmont T, Ferrari L, Duncan LR, Hawser S, et al. In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii. Antibiotics. 2022; 11(9):1201. https://doi.org/10.3390/antibiotics11091201

Chicago/Turabian Style

Michaeli, Janna, Shira Mandel, Shelly Maximov, Jonathan Zazoun, Paola Savoia, Nimmi Kothari, Thomas Valmont, Livia Ferrari, Leonard R. Duncan, Stephen Hawser, and et al. 2022. "In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii" Antibiotics 11, no. 9: 1201. https://doi.org/10.3390/antibiotics11091201

APA Style

Michaeli, J., Mandel, S., Maximov, S., Zazoun, J., Savoia, P., Kothari, N., Valmont, T., Ferrari, L., Duncan, L. R., Hawser, S., Cohen-Kutner, M., & Bachnoff, N. (2022). In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii. Antibiotics, 11(9), 1201. https://doi.org/10.3390/antibiotics11091201

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop